Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 134,06 € (-31,37 %). La mediana es de 122,74 € (-37,17 %).
| Comprar |
7 |
| Mantener |
16 |
| Vender |
6 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Moderna beats Q3 expectations and raises full-year guidance
Moderna reported third-quarter revenue up 29% to $1.3 billion and net income of $162 million, far above the expected $885 million in revenue and an anticipated loss. The company raised its revenue forecast for the fiscal year to a gain of 15–25% and updated its year‑end cash expectation to $8.1–8.3 billion. The strong results pushed the stock sharply higher in premarket trading. » Más en deraktionaer.de
Moderna posts over 650% year-to-date gain in 2026, ahead of Micron and Nvidia
Moderna shares have risen more than 650% year-to-date, significantly outperforming names like Micron and Nvidia. Drivers include mRNA technology, successful COVID-19 revenues and a diversified pipeline with respiratory vaccines, oncology programs and treatments for rare diseases. Attention is focused on Intismeran autolog and a phase‑3 combination with Keytruda in melanoma; on November 6 Moderna will release quarterly results and has confirmed revenue growth of up to 10% for the year. Investors are expecting further details on the flu vaccine and the oncology opportunities. » Más en deraktionaer.de
Moderna delivers 197.82% return for investors since October 2023
An investment of $10,000 in Moderna on October 29, 2023 (closing price $71.91) would have grown to $29,782.37 by October 28, 2026 at a share price of $214.17. That corresponds to an increase of the original investment by 197.82%. Moderna was most recently valued at $85.63 billion; stock splits and dividends were not taken into account in the calculation. » Más en finanzen.net
AstraZeneca to enter cancer vaccines and go head-to-head with Moderna and Merck
AstraZeneca announces plans to push into the cancer-vaccine business, driven by the success of personalized mRNA therapies from Moderna and Merck. CEO Pascal Soriot points to years of mRNA research, while oncology chief Dave Fredrickson concedes that competitors are currently further ahead. AstraZeneca is focusing on areas with high quality, pioneering roles and scale effects; the infectious-disease division will concentrate on non-personalized vaccines. The stock has recovered after consolidation, with the 200-day moving average at just under 13,500 pence an important technical hurdle; dividend yield around 2.0%, quarterly report on October 30. » Más en deraktionaer.de
Moderna shares fall after analyst downgrade and cautious data on Intismeran
Moderna shares drop about eight percent, extending a correction after preliminary Intismeran data leaked. William Blair removed its buy rating and downgraded to "Market Perform", saying the success of the personalized melanoma vaccine still needs to be demonstrated in other tumor types. Analysts see potential for a new treatment standard but warn of substantial clinical and biological risks in expanding to kidney, bladder and lung cancer. » Más en deraktionaer.de
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 1159,18 M | 33,89 % |
| Beneficio bruto | 878,44 M | 12.785,89 % |
| Beneficio neto | 143,02 M | 183,92 % |
| EBITDA | 211 M | 283,42 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 82,18 mil M € |
Número de acciones | 404,62 M |
Máximo/mínimo de 52 semanas | 255,31 € - 20,26 € |
| Dividendos | No |
Beta | 0,90 |
Ratio P/E | -31,59 |
Ratio PEG | -3,20 |
Ratio P/B | 13,10 |
Ratio P/S | 35,79 |
Perfil de la empresa
Moderna, Inc., una empresa de biotecnología, descubre, desarrolla y comercializa terapias y vacunas basadas en ARN mensajero para el tratamiento de enfermedades infecciosas, inmunooncología, enfermedades raras, enfermedades cardiovasculares y enfermedades autoinmunes en Estados Unidos, Europa e internacionalmente. Sus vacunas respiratorias incluyen las de COVID-19, gripe, virus sincitial respiratorio, HCoV endémico y hMPV+PIV3; las vacunas latentes comprenden las de citomegalovirus, virus de Epstein-Barr, virus de la inmunodeficiencia humana, virus del herpes simple y virus varicela-zóster; y las vacunas de salud pública consisten en las de Zika y Nipah. La empresa también ofrece terapias sistémicas secretadas y de superficie celular; vacunas contra el cáncer, como las personalizadas contra el cáncer, KRAS y de puntos de control; productos intratumorales de inmunooncología; y terapias localizadas regenerativas, sistémicas intracelulares e inhaladas de uso pulmonar. Tiene alianzas estratégicas con AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; la Agencia de Proyectos de Investigación Avanzada de Defensa; la Autoridad de Investigación y Desarrollo Biomédico Avanzado; Institute for Life Changing Medicines; y la Fundación Bill & Melinda Gates, además de un acuerdo de colaboración y licencia con Chiesi Farmaceutici S.P.A. La empresa antes se conocía como Moderna Therapeutics, Inc. y cambió su nombre a Moderna, Inc. en agosto de 2018. Moderna, Inc. fue fundada en 2010 y tiene su sede en Cambridge, Massachusetts.
| Nombre | Moderna Inc. |
| CEO | Stéphane Bancel |
| Sede | Cambridge,
ma Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Biotecnología |
| Salida a bolsa | 07/12/2018 |
| Empleados | 4700 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | MRNA |
XETRA | 0QF.F |
Frankfurt | 0QF.F |
Düsseldorf | 0QF.DU |
Hamburg | 0QF.HM |
Milan | 1MRNA.MI |
London | 0A45.L |
SIX | 0QF.SW |
München | 0QF.MU |
Wien | MRNA.VI |